1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
2
|
Carioli G, Negri E, Kawakita D, Garavello
W, La Vecchia C and Malvezzi M: Global trends in nasopharyngeal
cancer mortality since 1970 and predictions for 2020: Focus on
low-risk areas. Int J Cancer. 140:2256–2264. 2017. View Article : Google Scholar : PubMed/NCBI
|
3
|
Sun P, Chen C, Chen XL, Cheng YK, Zeng L,
Zeng ZJ, Liu LZ, Su Y and Gu MF: Proposal of a clinical typing
system and generation of a prognostic model in patients with
nasopharyngeal carcinoma from Southern China. J BUON. 19:474–483.
2014.PubMed/NCBI
|
4
|
Liang WJ, Qiu F, Hong MH, Guo L, Qin HD,
Liu QC, Zhang XS, Mai HQ, Xiang YQ, Min HQ, et al: Differentially
expressed genes between upward and downward progressing types of
nasopharyngeal carcinoma. Chin J Cancer. 27:460–465. 2008.(In
Chinese).
|
5
|
Mo L, Weng J, Zeng F, Li X, Liu B, Li Z
and Kuang G: The relationship between extend types and distant
metastasis of nasopharyngeal carcinoma. Lin Chung Er Bi Yan Hou Tou
Jing Wai Ke Za Zhi. 24:554–555, 558. 2010.(In Chinese). PubMed/NCBI
|
6
|
Chew MM, Gan SY, Khoo AS and Tan EL:
Interleukins, laminin and Epstein - Barr virus latent membrane
protein 1 (EBV LMP1) promote metastatic phenotype in nasopharyngeal
carcinoma. BMC Cancer. 10:5742010. View Article : Google Scholar : PubMed/NCBI
|
7
|
Morrissey MA, Jayadev R, Miley GR, Blebea
CA, Chi Q, Ihara S and Sherwood DR: SPARC promotes cell invasion in
vivo by decreasing type IV collagen levels in the basement
membrane. PLoS Genet. 12:e10059052016. View Article : Google Scholar : PubMed/NCBI
|
8
|
Tanjore H and Kalluri R: The role of type
IV collagen and basement membranes in cancer progression and
metastasis. Am J Pathol. 168:715–717. 2006. View Article : Google Scholar : PubMed/NCBI
|
9
|
Timpl R, Wiedemann H, van Delden V,
Furthmayr H and Kühn K: A network model for the organization of
type IV collagen molecules in basement membranes. Eur J Biochem.
120:203–211. 1981. View Article : Google Scholar : PubMed/NCBI
|
10
|
Mundel TM and Kalluri R: Type IV
collagen-derived angiogenesis inhibitors. Microvasc Res. 74:85–89.
2007. View Article : Google Scholar : PubMed/NCBI
|
11
|
Khoshnoodi J, Pedchenko V and Hudson BG:
Mammalian collagen IV. Microsc Res Tech. 71:357–370. 2008.
View Article : Google Scholar : PubMed/NCBI
|
12
|
Ikeda K, Iyama K, Ishikawa N, Egami H,
Nakao M, Sado Y, Ninomiya Y and Baba H: Loss of expression of type
IV collagen alpha5 and alpha6 chains in colorectal cancer
associated with the hypermethylation of their promoter region. Am J
Pathol. 168:856–865. 2006. View Article : Google Scholar : PubMed/NCBI
|
13
|
Tanaka K, Iyama K, Kitaoka M, Ninomiya Y,
Oohashi T, Sado Y and Ono T: Differential expression of alpha
1(IV), alpha 2(IV), alpha 5(IV) and alpha 6(IV) collagen chains in
the basement membrane of basal cell carcinoma. Histochem J.
29:563–570. 1997. View Article : Google Scholar : PubMed/NCBI
|
14
|
Dehan P, Waltregny D, Beschin A, Noel A,
Castronovo V, Tryggvason K, De Leval J and Foidart JM: Loss of type
IV collagen alpha 5 and alpha 6 chains in human invasive prostate
carcinomas. Am J Pathol. 151:1097–1104. 1997.PubMed/NCBI
|
15
|
Pan XX, Tong LH, Chen YF, Li FL, Tang WB,
Liu YJ and Yang WA: simplified T classification based on the 8th
edition of the UICC/AJCC staging system for nasopharyngeal
carcinoma. Cancer Manag Res. 11:3163–3169. 2019. View Article : Google Scholar : PubMed/NCBI
|
16
|
Zhang G, Fedyunin I, Kirchner S, Xiao C,
Valleriani A and Ignatova Z: FANSe: An accurate algorithm for
quantitative mapping of large scale sequencing reads. Nucleic Acids
Res. 40:e832012. View Article : Google Scholar : PubMed/NCBI
|
17
|
Huang W, Sherman BT and Lempicki RA:
Systematic and integrative analysis of large gene lists using DAVID
bioinformatics resources. Nat Protoc. 4:44–57. 2009. View Article : Google Scholar : PubMed/NCBI
|
18
|
Yu G, Wang LG, Han Y and He QY:
clusterProfiler: An R package for comparing biological themes among
gene clusters. OMICS. 16:284–287. 2012. View Article : Google Scholar : PubMed/NCBI
|
19
|
Nagy Á, Lánczky A, Menyhárt O and Győrffy
B: Validation of miRNA prognostic power in hepatocellular carcinoma
using expression data of independent datasets. Sci Rep. 8:92272018.
View Article : Google Scholar : PubMed/NCBI
|
20
|
Wei X, Li S, He J, Du H, Liu Y, Yu W, Hu
H, Han L, Wang C, Li H, et al: Tumor-secreted PAI-1 promotes breast
cancer metastasis via the induction of adipocyte-derived collagen
remodeling. Cell Commun Signal. 17:582019. View Article : Google Scholar : PubMed/NCBI
|
21
|
Guo S and Deng CX: Effect ofstromal cells
in tumor microenvironment on metastasis initiation. Int J Biol Sci.
14:2083–2093. 2018. View Article : Google Scholar : PubMed/NCBI
|
22
|
Kaur A, Ecker BL, Douglass SM, Kugel CH
III, Webster MR, Almeida FV, Somasundaram R, Hayden J, Ban E,
Ahmadzadeh H, et al: Remodeling of the collagen matrix in aging
skin promotes melanoma metastasis and affects immune cell motility.
Cancer Discov. 9:64–81. 2019. View Article : Google Scholar : PubMed/NCBI
|
23
|
Chelberg MK, Tsilibary EC, Hauser AR and
McCarthy JB: Type IV collagen-mediated melanoma cell adhesion and
migration: Involvement of multiple, distinct domains of the
collagen molecule. Cancer Res. 49:4796–4802. 1989.PubMed/NCBI
|
24
|
Hamano Y, Zeisberg M, Sugimoto H, Lively
JC, Maeshima Y, Yang C, Hynes RO, Werb Z, Sudhakar A and Kalluri R:
Physiological levels of tumstatin, a fragment of collagen IV alpha3
chain, are generated by MMP-9 proteolysis and suppress angiogenesis
via alphaV beta3 integrin. Cancer Cell. 3:589–601. 2003. View Article : Google Scholar : PubMed/NCBI
|
25
|
Hamano Y and Kalluri R: Tumstatin, the NC1
domain of alpha3 chain of type IV collagen, is an endogenous
inhibitor of pathological angiogenesis and suppresses tumor growth.
Biochem Biophys Res Commun. 333:292–298. 2005. View Article : Google Scholar : PubMed/NCBI
|
26
|
Maeshima Y, Colorado PC and Kalluri R: Two
RGD-independent alpha vbeta 3 integrin binding sites on tumstatin
regulate distinct anti-tumor properties. J Biol Chem.
275:23745–23750. 2000. View Article : Google Scholar : PubMed/NCBI
|
27
|
Zhang GM, Zhang YM, Fu SB, Liu XH, Fu X,
Yu Y and Zhang ZY: Effects of cloned tumstatin-related and
angiogenesis-inhibitory peptides on proliferation and apoptosis of
endothelial cells. Chin Med J (Engl). 121:2324–2330. 2008.
View Article : Google Scholar : PubMed/NCBI
|
28
|
Maeshima Y, Yerramalla UL, Dhanabal M,
Holthaus KA, Barbashov S, Kharbanda S, Reimer C, Manfredi M,
Dickerson WM and Kalluri R: Extracellular matrix-derived peptide
binds to alphavbeta3 integrin and inhibits
angiogenesis. J Biol Chem. 276:31959–31968. 2001. View Article : Google Scholar : PubMed/NCBI
|
29
|
Maeshima Y, Sudhakar A, Lively JC, Ueki K,
Kharbanda S, Kahn CR, Sonenberg N, Hynes RO and Kalluri R:
Tumstatin, an endothelial cell-specific inhibitor of protein
synthesis. Science. 295:140–143. 2002. View Article : Google Scholar : PubMed/NCBI
|
30
|
Pasco S, Ramont L, Venteo L, Pluot M,
Maquart FX and Monboisse JC: In vivo overexpression of tumstatin
domains by tumor cells inhibits their invasive properties in a
mouse melanoma model. Exp Cell Res. 301:251–265. 2004. View Article : Google Scholar : PubMed/NCBI
|
31
|
Hou P, Chen Y, Ding J, Li G and Zhang H: A
novel mutation of COL4A3 presents a different contribution to
Alport syndrome and thin basement membrane nephropathy. Am J
Nephrol. 27:538–544. 2007. View Article : Google Scholar : PubMed/NCBI
|
32
|
Rana K, Tonna S, Wang YY, Sin L, Lin T,
Shaw E, Mookerjee I and Savige J: Nine novel COL4A3 and COL4A4
mutations and polymorphisms identified in inherited membrane
diseases. Pediatr Nephrol. 22:652–657. 2007. View Article : Google Scholar : PubMed/NCBI
|
33
|
Saravani R, Yari D, Saravani S and
Hasanian-Langroudi F: Correlation between the COL4A3, MMP-9, and
TIMP-1 polymorphisms and risk of keratoconus. Jpn J Ophthalmol.
61:218–222. 2017. View Article : Google Scholar : PubMed/NCBI
|
34
|
Saravani S, Yari D, Saravani R and Azadi
Ahmadabadi C: Association of COL4A3 (rs55703767), MMP-9
(rs17576)and TIMP-1 (rs6609533) gene polymorphisms with
susceptibility to type 2 diabetes. Biomed Rep. 6:329–334. 2017.
View Article : Google Scholar : PubMed/NCBI
|
35
|
Hao XD, Chen XN, Zhang YY, Chen P, Wei C,
Shi WY and Gao H: Multi-level consistent changes of the ECM pathway
identified in a typical keratoconus twins family by multi-omics
analysis. Orphanet J Rare Dis. 15:2272020. View Article : Google Scholar : PubMed/NCBI
|
36
|
Jiang CP, Wu BH, Chen SP, Fu MY, Yang M,
Liu F and Wang BQ: High COL4A3 expression correlates with poor
prognosis after cisplatin plus gemcitabine chemotherapy in
non-small cell lung cancer. Tumour Biol. 34:415–420. 2013.
View Article : Google Scholar : PubMed/NCBI
|
37
|
Nie XC, Wang JP, Zhu W, Xu XY, Xing YN, Yu
M, Liu YP, Takano Y and Zheng HC: COL4A3 expression correlates with
pathogenesis, pathologic behaviors, and prognosis of gastric
carcinomas. Hum Pathol. 44:77–86. 2013. View Article : Google Scholar : PubMed/NCBI
|